A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

Inclusion Criteria: * Male or female participants aged 12 years or older * Provision of signed and dated written informed consent, including assent for minors * Prescribed treatment with Tezepelumab * Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses * Received at least one prescription of medium-dose to high-dose inhaled corticosteroids (ICS) during the 52 weeks prior to enrolment date * Use of additional asthma maintenance controller medication(s) for at least 52 weeks prior to enrolment date * Documented history of at least 1 asthma exacerbations during the 52 weeks prior to enrolment date * Individuals with ACQ-6 score ≥ 1.5 (indicating inadequate asthma symptom control) at enrolment or up to 12 weeks before enrolment * Participants currently receiving care from pulmonologists and/or allergists * Participants who are able to understand and complete the ePROs * Availability of participants medical records for asthma exacerbation and Healthcare Resource Utilization (HCRU) for the 52 weeks prior to Tezepelumab initiation Exclusion Criteria: * Any contraindication to Tezepelumab * Participants on concurrent biologics for asthma at the time of receiving the first dose of Tezepelumab will be excluded except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment) * Participation in an observational study that might, in the Investigator's …